

47

— SSMO, SSH — Joint Session

#### **Oral presentations Clinical hemato-oncology**

Wednesday, 19 Nov 2025, 3:45 p.m. - 5:15 p.m., Shanghai 1-2

Chair: Sacha Zeerleder (Luzerner Kantonsspital), Mascha Binder (Unispital Basel)

#### Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: A Real-World Analysis from a Single Center

Presentation time: 9 min Discussion time: 3 min

Speaker: Shaforostova (Inselspital)

### Real world experience with maintenance treatment after allogeneic hematopoetic cell transplantation for myeloid neoplasia

Presentation time: 9 min Discussion time: 3 min

Speaker: Sakiz (University Hospital Basel)

#### AL-amyloidosis patients continue to benefit from HDCT with ASCT compared to chemoimmunotherapy only in the daratumumab era.

Presentation time: 9 min Discussion time: 3 min Speaker: Bee (Inselspital)

### Cyclophosphamide-ATG Compared to BEAM-ATG as Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Presentation time: 9 min Discussion time: 3 min

Speaker: Koch (University of Zurich and University Hospital Zurich)

#### Performance of ELN Risk Stratifications in a Real-World Setting: A 20-year Analysis of Patients with Acute Myeloid Leukaemia

Presentation time: 9 min Discussion time: 3 min

Speaker: Zimmermann (UniversitätsSpital Zürich)

## Longterm-outcome of myeloma patients after high-dose chemotherapy with melphalan alone versus melphalan with bendamustine.

Presentation time: 9 min Discussion time: 3 min

Speaker: Fischer (Inselspital)



# Swiss Real-World Experience with Tafasitamab and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The SWISS-MIND Study

Presentation time: 9 min Discussion time: 3 min

Speaker: Gassmann (University of Basel)